research Results of stage I in a phase II randomized bilateral comparison of bexarotene 1% topical gel in alopecia areata
Bexarotene 1% topical gel helped some patients with alopecia areata regrow hair.
Search
forProducts matching "stage ii alopecia"
Tracking 4 products like 183 PROPECIA 1MG/*28 TABL, 183 PROPECIA 1MG/*28 TABL, 183 PROPECIA 1MG/*28 TABL and 183 PROPECIA 1MG/*28 TABL from by companies like OnlinePharmacy-BG, Inhouse Pharmacy, oasisstad.net and oxfordon line pharmacy. View all 4 products »Research
5 / 1000+ results research 307 Computer-assisted epitope prediction revealed potential autoantigens associated with human alopecia areata
Melanogenesis-related proteins may trigger immune responses in alopecia areata patients.
research Exploring the hair follicle immune privilege state in nonsegmental vitiligo
Hair follicles in nonsegmental vitiligo are better protected from immune attacks than in alopecia areata.
research Abuso infantil: aspectos conductuales y otros problemas relacionados
Androgenetic alopecia is a common cause of hair loss, with treatments like minoxidil and hair transplantation available, and new therapies are being developed.
research Clinical and histological challenge in the differential diagnosis of diffuse alopecia: female androgenetic alopecia, telogen effluvium and alopecia areata – part II
Diagnosing diffuse alopecia, a hair loss condition, can be challenging and may require a scalp biopsy or tracking the disease's progression when symptoms and skin tests aren't enough.
Community Join
5 / 1000+ resultscommunity CASSIOPEA ANNOUNCES VERY POSITIVE PHASE II TWELVE MONTHS RESULTS FOR BREEZULA® (CLASCOTERONE) IN TREATING ANDROGENETIC ALOPECIA
Clascoterone (Breezula) showed positive results for treating hair loss without affecting cortisol levels. Opinions vary, with some users optimistic about its potential and others critical of its effectiveness compared to existing treatments like finasteride.
community Kintor Pharma Announces Completion of Patient Enrollment in Phase II Clinical Trial of GT20029 for Treatment of Androgenetic Alopecia in China
Kintor Pharma completed patient enrollment for a Phase II trial in China for GT20029, a potential new treatment for hair loss. Some believe GT20029 could replace finasteride if effective, while others discuss finasteride's limited efficacy and potential underreported side effects.
community Kintor Pharma Announces Successful Completion of Phase II Clinical Trial of KX-826 for Treatment of Androgenetic Alopecia in the US
Kintor Pharma announced successful Phase II trial results for KX-826 in treating hair loss, showing it's comparable to finasteride and can be used with it. Some participants saw a 10 hair/cm^2 increase, which is considered a good outcome at the low dose used.
community Phase II for Technoderma Therepeutic's TDM-105795 set to begin in April tentatively
Phase II for TDM-105795 for Androgenic Alopecia is set to begin in April 2023. The study aims to evaluate the efficacy and safety of TDM-105795 in male subjects.
community KX-826 1% Phase II Results from China Just Dropped
KX-826 (Pyrilutamide) 0.5% and 1.0% solutions showed promising results in increasing hair count for male androgenetic alopecia, with the 0.5% dose slightly outperforming the 1% dose. The treatment was well-tolerated with no sexual side effects, but skepticism remains due to past inconsistencies in trial results.
Learn
5 / 16 resultslearn Overview
learn HMI-115
much-hyped research compound targeting prolactin receptor in scalp
learn GT20029
research compound made to degrade androgen receptors in scalp
learn Osteopontin
signaling protein that, when suppressed, may grow hair by reducing inflammation and stem cell loss
learn Dutasteride
Heavy duty finasteride that comes with higher risks, but scalp injections seem safe and are gaining popularity
Clinics
3 / 3 results
Experts
— no results